LUX-Head&Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy
Condition: Head and Neck Neoplasms · Sponsor: Boehringer Ingelheim
About this study
This randomized, open-label, phase III study will be performed in patients with recurrent and/or metastatic head and neck cancer which has progressed after platinum-based therapy. The objectives of this trial are to compare the efficacy and safety of afatinib versus methotrexate.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (53)
| Beijing Chao-Yang Hospital | Beijing, China | — |
| Cancer Hospital of Chinese Academy of Medical Science | Beijing, China | — |
| Navy General Hospital | Beijing, China | — |
| Peking Union Medical College Hospital | Beijing, China | — |
| The First Affiliated Hospital Of Bengbu Medical College | Bengbu, China | — |
| The First Hospital of Jilin University | Changchun, China | — |
| Sichuan Cancer Hospital | Chengdu, China | — |
| West China Hospital | Chengdu, China | — |
| Sun Yat-Sen University Cancer Center | Guangzhou, China | — |
| Zhejiang Cancer Hospital | Hangzhou, China | — |
| Harbin Medical University Cancer Hospital | Harbin, China | — |
| the 81th Hospital of PLA | Nanjing, China | — |
+ 41 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT01856478